Island Pharmaceuticals Limited (ASX:ILA)

Market Cap	48.40M
Revenue (ttm)	399.37K
Net Income (ttm)	-3.24M
Shares Out	236.09M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	937,509
Average Volume	483,246
Open	0.2200
Previous Close	0.2300
Day's Range	0.1900 - 0.2200
52-Week Range	0.0580 - 0.2800
Beta	0.16
RSI	50.14
Earnings Date	May 28, 2025

About Island Pharmaceuticals

Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a collaboration agreement with Monash University and National Cancer Institute IND. It also has a cooperative research and development agreement with the U.S. Army, Island in preparation for its Pha...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ILA